Little patients, losing patience: pediatric cancer drug development

The December 2004 Food and Drug Administration (FDA) approval of clofarabine (Clolar, Genzyme) for refractory pediatric acute lymphoblastic leukemia was a milestone in the history of pediatric cancer drug development. A rare occurrence, it represented approval of a new cancer drug for a pediatric

[1]  Andrew A. Signore,et al.  Pharmaceutical Industry Profile , 2005 .

[2]  A. Maniatis.  Progress in the treatment of myelodysplastic syndromes. , 2008, Blood transfusion = Trasfusione del sangue.

[3]  S. Hirschfeld,et al.  Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Christian,et al.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[6]  D. Green,et al.  Late effects of treatment for childhood cancer , 1992 .

[7]  Adolph E. Christ,et al.  Childhood cancer , 2020, The Downstate Series of Research in Psychiatry and Psychology.

[8]  M. Meadows.  Drug research and children. , 2003, FDA consumer.

[9]  A. Jemal,et al.  Cancer Statistics, 2004 , 2004, CA: a cancer journal for clinicians.

[10]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.